Quantcast

Contract Research Organization WCCT Global Welcomes Edward Kim as Executive Director, Early Clinical Development

November 5, 2013

WCCT Global announces Edward Kim as Executive Director of Early Clinical Development.

Costa Mesa, Ca (PRWEB) November 05, 2013

WCCT Global (WCCTG) is pleased to announce and welcome Mr. Edward Kim as Executive Director, Early Clinical Development. Ed will be overseeing the WCCTG, Cypress and Costa Mesa Clinical Pharmacology Research Units. As a Contract Research Organization professional Mr. Kim has over 17 years of Early Phase clinical research experience in both academia and the site/CRO industry. Nearly 15 years of his career was with California Clinical Trials/Parexel International, where he served as Director of Clinical Operations. He was responsible for managing all clinical operations (Clinical Research Teams, Pharmacy, Laboratory, and Nursing) for their expanded 100+ beds across their 3 Phase I units. Mr. Kim has conducted over 400 clinical trials supporting CNS indications, Asian ethnobridging, “CSF-dynabridging” programs, and various specialized programs in healthy normal populations. When asked how Ed felt to be joining WCCT Global, he replied, “I am extremely excited to be joining this dynamic and growing organization, and look forward to leveraging my background and knowledge in this space to help WCCTG continue to grow.”

“This is another great addition to WCCT Global,” exclaimed Jon Rojas, WCCTG’s Chief Operating Officer, “because this service offering is part of WCCTG’s core business which continues to grow. Having team members like Mr. Kim is why we are contacted by sponsors all over the world to perform clinical studies in many different therapeutic areas.”

More about WCCT Global:

WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like to request information how WCCT Global can assist your organization with your next clinical study, click here.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11300059.htm


Source: prweb



comments powered by Disqus